#Sino Biological #XPressMAX #Cell-Free

Sino Biological Introduces the XPressMAX™ Cell-Free Protein Synthesis Kit

Sino Biological, Inc., recognized as a leader in recombinant technology, has recently launched an innovative product aimed at transforming the landscape of antibody drug discovery. The new XPressMAX™ Cell-Free Protein Synthesis Kit is designed to significantly enhance the speed and efficiency of high-throughput screening processes powered by artificial intelligence (AI). This cutting-edge kit represents a leap forward in research methodologies by reducing the complexities associated with traditional cell-based expression systems.

Rapid and Efficient Protein Production

One of the standout features of the XPressMAX™ kit is its ability to synthesize proteins in as little as three hours, allowing researchers to conduct experiments and screenings at an unprecedented pace. This rapid synthesis is achieved through an advanced cell-free protein synthesis technology, which effectively streamlines the in vitro production of target proteins and antibodies. By eliminating the various limitations imposed by conventional methods, the XPressMAX™ kit facilitates a much faster journey from discovery to validation.

The kit utilizes an E. coli lysate that includes all the necessary components for transcription and translation. This feature allows researchers to perform direct protein synthesis from plasmid or PCR templates, enabling them to quickly validate and express vital formats of antibodies, such as VHH, scFv, Fab, and Miniproteins. With this robust technology, Sino Biological has set up a system capable of validating over 2,000 scFv/VHH molecules in a mere three to four weeks.

Enhancing AI-Driven Discovery

In the realm of AI-powered drug discovery, the demand for fast and reliable protein expression systems is more critical than ever. As noted by Dr. Jie Zhang, the General Manager of Sino Biological,